Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.08.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Akihiro Fujimoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: afujimot@saitama-med.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant systemic therapy (NST) is the standard of care for high-risk early triple-negative breast cancer (TNBC). Although pathological complete response (pCR) is strongly associated with improved survival, reliable and accessible predictors of response remain limited. The aim of this study was to evaluate whether peripheral blood immune markers and tumor-infiltrating lymphocytes (TILs) can predict pCR in patients with TNBC treated with neoadjuvant pembrolizumab plus chemotherapy. MATERIALS AND METHODS: In this single-institution retrospective study, 60 patients with stage II-III TNBC received NST according to the KEYNOTE-522 regimen followed by curative surgery. Pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and TIL levels were assessed. Associations with pCR were analyzed using logistic regression models. RESULTS: Thirty-six patients (60.0%) achieved pCR. In the univariate analysis, low NLR, high TILs, and histological type were significantly associated with pCR, whereas PLR was not. Multivariate analysis identified low NLR and histological type as independent predictors of pCR. Patients with both low NLR and high TILs demonstrated the highest pCR rate. CONCLUSION: NLR may be a simple and accessible predictor of pCR in patients with TNBC receiving neoadjuvant pembrolizumab plus chemotherapy. Combining peripheral blood immune markers with intratumoral immune parameters may enhance treatment stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: afujimot@saitama-med.ac.jp.
- Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
- Department of Breast Oncology, Saitama Medical University Hospital, Iruma-gun, Japan.
Zitieren
APA
Fujimoto, A., Ichinose, Y., Matsuura, K., Mikami, E., Inohana, W., Kurosawa, T., Nakame, A., Sakakibara, A., Nukui, A., Asano, A., Shimada, H., Yokogawa, H., Ohara, M., Ishiguro, H., Hasebe, T., Osaki, A., & Saeki, T. (2026). Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.08.013
Vancouver
Fujimoto A, Ichinose Y, Matsuura K, Mikami E, Inohana W, Kurosawa T, et al. Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.08.013
BibTeX
@article{Fujimoto2026,
author = {Fujimoto, Akihiro and Ichinose, Yuki and Matsuura, Kazuo and Mikami, Emi and Inohana, Wakako and Kurosawa, Taeko and Nakame, Ayako and Sakakibara, Ayaka and Nukui, Asami and Asano, Aya and Shimada, Hiroko and Yokogawa, Hideki and Ohara, Masahiro and Ishiguro, Hiroshi and Hasebe, Takahiro and Osaki, Akihiko and Saeki, Toshiaki},
title = {Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.08.013}
}
EUVIMED